deltatrials
Terminated PHASE2 INTERVENTIONAL 3-arm NCT02888756

iHIVARNA Clinical Trial in HIV Infected Individuals (iHIVARNA-01)

A Phase IIa Randomized, Placebo Controlled, Double Blinded Study to Evaluate the Safety and Immunogenicity of iHIVARNA-01 in Chronically HIV-infected Patients Under Stable Combined Antiretroviral Therapy

Sponsor: Asphalion

Conditions HIV Infections
Interventions Placebo TriMix iHIVARNA-01
Updated 12 times since 2017 Last updated: Dec 11, 2019 Started: Apr 4, 2017 Primary completion: Feb 12, 2018 Completion: Feb 12, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Interim analysis did not show sufficient immunogenicity of IMP compared to placebo

Other HIV Infections trials with similar outcome

Browse all HIV Infections trials

Listed as NCT02888756, this PHASE2 trial focuses on HIV Infections and remains terminated or withdrawn. Sponsored by Asphalion, it has been updated 12 times since 2017, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

~Jan 2017 – ~Jun 2017 · 5 months · monthly snapshotNot Yet Recruiting~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshotRecruiting~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshotActive Not Recruiting~Sep 2017 – ~Dec 2017 · 3 months · monthly snapshotRecruiting~Dec 2017 – ~Mar 2018 · 3 months · monthly snapshotActive Not Recruiting~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2020 · 19 months · monthly snapshotTerminated~Jan 2020 – ~Jan 2021 · 12 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotTerminated~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

12 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE2

  5. Jan 2020 — Jan 2021 [monthly]

    Terminated PHASE2

▶ Show 7 earlier versions

  1. Jun 2018 — Jan 2020 [monthly]

    Terminated PHASE2

  2. Mar 2018 — Jun 2018 [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  3. Dec 2017 — Mar 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Sep 2017 — Dec 2017 [monthly]

    Recruiting PHASE2

    Status: Active Not Recruiting → Recruiting

  5. Aug 2017 — Sep 2017 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  6. Jun 2017 — Aug 2017 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  7. Jan 2017 — Jun 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Asphalion
  • CR2O
  • Germans Trias i Pujol Hospital
  • Hospital Clinic of Barcelona
  • Institut d'Investigacions Biomèdiques August Pi i Sunyer
  • Institute of Tropical Medicine, Belgium
  • IrsiCaixa
  • Rob Gruters
  • Synapse bv
  • Universitair Ziekenhuis Brussel
  • Vrije Universiteit Brussel
  • eTheRNA immunotherapies
Data source: Erasmus Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations